国外头孢菌素市场浅析任吉民

2005164ChinaPharmacy2005Vol.16No.4·255·*。:。:0311-5993999AbroadMarketAnalysisofCephalosporinRENJiming,ZHANGZengmei,LIHua,ZHGNGLi(NorthChinaPharmaceuticalGroupCorporation,Shiji-azhuang050015,China)ABSTRACTOBJECTIVE:Toinvestigatethecurrentabroadmarketstateofthecephalosporinanditstrendofdevelop-ment.METHODS:Thecephalosporinabroadwasanalyzedinaspectsofgeneralsalessituation,productsstructure,researchanddevelopment,andthemanufacturesituation.RESULTSCONCLUSION:Thesalesvolumeofthecephalosporinabroadhasbeendecreasingannually,itspredominancepositionovertheotherantibioticshasbeenlosing.Thefuturedevelopmentre-searchtrendofantibioticsisbroad-spectrum,high-effectiveslow-releasedoralpreparations.KEYWORDSCephalosporin;Abroad;Market2070,,,。、、,。1,,40%,。1995,102.20;199870.73,5,19971.2%。,,。199973.48,19983.9%。200167.00(),2000,2%。,(45%),(15%)、(11%)、(6%)、(5%)、(18%)。,49.34%,45.2%,53.9%[1]。1[2,3]。1,,,200110.05,48;20029.94,20011.1%,55;200310.22,20022.8%,64。,20015.89,100;20023.65,200138.0%,174;20034.04,200210.7%,,174。,20013———3.63,4.90,3.01,,,,。1———、,3～51。1995～2002,123(、、、4,1998)7,12。4———(1995～2000),42.3%;3———(1995～2001)14.4%,(1995～2000)9.5%;1———(1995～2000)3.9%;3———1.4%1.2%。,—25.2%;3(1995～2002)—14.4%;1(1995～2000)—10.9%;3(1995～2000)—10.1%,(1995～2000)—8.3%;2—6.4%;1—4.5%。、,,··国外头孢菌素市场浅析任吉民*,张增梅,李华,张立(华北制药集团公司,石家庄市050015)R978.1+1C1001-0408(2005)04-0255-03目的:评估国外头孢菌素的市场现状及发展趋势。方法:对国外头孢菌素的销售、产品结构、研发及生产状况进行分析。结果与结论:近年来,国外头孢菌素市场单品种销售额逐年减少,头孢菌素在抗生素中的优势地位逐年下降,今后的研发方向是广谱、高效、长效和口服制剂等。头孢菌素;国外;市场·256·ChinaPharmacy2005Vol.16No.420051641()Tab1Thesalesvolumeofabroadcephalosporinoverthepastyears(hundredmilliondollars)199519961997199819992000200120022003(%)1995～2002(%)4.503.353.03/5.505.504.90//-10.91.45.806.406.49/6.806.525.893.654.0410.7-6.41.52/1.39/1.321.21///-8.3-4.50.600.550.55//////001.001.691.62/1.121.21///-8.03.99.159.3310.11/11.9810.1210.059.9410.222.81.21.622.153.18/4.023.913.63//-7.214.42.00/2.73/3.313.15///-4.89.53.504.494.26/3.763.233.01//-6.8-2.53.035.424.42/3.432.92///-14.9-0.72.142.51//1.651.20///-27.3-10.91.621.04//0.850.95///11.8-10.10.250.61//1.331.46///9.842.3////0.800.97///21.2/1.751.63//0.200.41///105.0-25.22.000.73//1.892.11///11.61.11.000.95//0.710.65///-8.5-8.3////0.500.48///-4.0/2.530.72//1.451.41///-2.8-11.00.600.83//0.700.54///-22.9-2.12.53///2.132.08///-2.3-3.8/1.591.39//1.411.30///-7.8-3.90.81//////////[4],。,1997～20022.1%,71.8%。2001100,8,2,48,10.05;100,5.89。2003100,6,1,64,10.22。、。,,。(2001～20054)3———、3。2、2.1,70,2060～70;2080～90,;2090β-、,。40、,56,113,215,324,44;,36,18,2。,40。2.2,。1985,1400,19954700,19985600,200010000。1998,2450、475、430、410、72。,,3%～4%,。2080,,。,。,,7-(7-ACA)。,7-ACA。,、“C、7-ACA”。(),、,。,,、7-ACA、ADM[5]。2.3,、,:,1991～200012,,1991～199510,19962;、,199318,20004。,、,,,,,。4,、、、。,、、、[6]。3,。1995～1999,、()、、4.00～6.80,2005164ChinaPharmacy2005Vol.16No.4·257·*(30371767)#,。:。:0379-4993651。E-mail:[e-mail]Δ。,。:。:023-68754435。E-mail:[e-mail]2000,,2003,4.04,174,()、、3.42,200。1995～2003,,,。[1],.β-[J].中国医药情报,2004,10(5):15.[2].2003200[J].中国医药技术与市场,2004,4(5):16.[3],.2002200[J].中国医药技术与市场,2003,3(5):23.[4].[J].中国药房,2004,15(9):528.[5],.[J].中国医药市场信息,2003,7:10.[6],.[J].天津药学,2003,15(6):52.(:2004-08-24:2004-10-13)··*吕根法#,卫国,郭毅斌,郑江Δ,肖光夏(第三军医大学西南医院中心实验室,重庆市400038)R284A1001-0408(2005)04-0257-03目的:利用生物传感技术从赤芍中分离抗内毒素单体成分。方法:以LipidA包被生物传感器样品池表面,建立筛选靶点,并以传感器上回收物的紫外扫描结果为参照,通过跟踪测定硅胶柱层析、高效液相色谱(HPLC)流出组分与LipidA的结合能力,分离抗内毒素的单体成分,并应用鲎试剂法测定单体成分与体外脂多糖(LPS)的中和作用。结果:从生物传感器回收到可与LipidA结合的组分,其紫外吸收峰分别为194、215、275nm波长。通过HPLC分离出与LipidA具有较高结合活性的单体成分为1,2,3,4,6—O—五没食子酰—β—D—葡萄糖(PGG),浓度为8、4、2μg/ml的PGG分别能够中和0.1EU/mlLPS活性的68.8%、43.7%、31.4%。结论:利用生物传感器技术,以LipidA为靶点分离赤芍抗内毒素单体成分是可行的,且具有高效、快速、准确等优点,适合于大规模地从中草药中分离抗内毒素的单体成分。生物传感技术;赤芍;内毒素;LipidAStudyofIsolatingAnti-EndotoxinMonomerComponentfromRadixPaeoniaeRubraBiosensorbyBiosensorTechniqueLUGenfa,WEIGuo,GUOYibin,ZHENGJiang,XIAOGuangxia(MedicalResearchCenter,SouthwesternHospital,TheThirdMilitaryMedicalUniversity,Chongqing400038,China)ABSTRACTOBJECTIVE:Toisolateanti-endotoxinmonomercomponentfromRadixPaeoniaeRubrabymeansofbiosen-sortechnique.METHODS:ThesurfaceofbiosensorcuvettewasembeddedbyLipidA;thescreeningtargetwasestablished,trackingthesilicagelcolumnchromatogramandthebindingabilityofeffluentcomponentfromHPLCwithLipidAwiththeultravioletscanresultofthereclaimedmaterialfrombiosensorasreference;anti-endotoxinmonomercomponentwasisolated;thecomponentofmonomerandthesyntheticactionofextrinsiclipopolysaccharideswerealsoassayedbyLALtestmethod.RESULTS:ComponentsbindingtoLipidAwasreclaimedfromcuveteebybiosensortechnique,withthewavelengthofUVabsorptionpeakat194nm,215nmand275nmrespectively.Anti-endotoxinmonomersofhigherbindingactivitywithLipidAisolatedbyHPLCmethodwere1,2,3,4,6—O—pentagalloyl—β—D—glucose(PGG).PGGatconcentrationof8,4,2μg/mlrespectivelyneutralized68.8%,43.7%and31.4%ofLPSatanactivityof0.1EU/mlrespectively.CONCLUSION:Itisfea-sibletoisolateanti-endotoxinmonomercomponentfromRadixPaeoniaeRubrabymeansofbiosensortechnique,whichisafast,accurateandefficientandcanbeusedtoisolateanti-endotoxinmonomercomponentfromRadixPaeo